A Comparison of Cardiovascular Benefits of Dapagliflozin and Empagliflozin in Type 2 Diabetes: A Systematic Review and Meta-analysis

Simple item page
dc.contributor.authorN. Benjamin
dc.contributor.authorAarushi Gupta
dc.contributor.authorTawfiq Turjman
dc.contributor.authorWajih Syed
dc.contributor.authorAnand Anghan
dc.contributor.authorChenny Koodarath
dc.contributor.authorNaseem Salahuddin
dc.contributor.authorMohammed M. Khawar
dc.contributor.authorAnirudh Y. Edu
dc.contributor.authorPiere Ray Tito Rodriguez
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T19:46:27Z
dc.date.available2026-03-22T19:46:27Z
dc.date.issued2025
dc.identifier.doi10.1007/s42399-025-02103-y
dc.identifier.urihttps://doi.org/10.1007/s42399-025-02103-y
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/78036
dc.language.isoen
dc.publisherSpringer Nature
dc.relation.ispartofSN Comprehensive Clinical Medicine
dc.sourceUniversity of Central Lancashire
dc.subjectDapagliflozin
dc.subjectEmpagliflozin
dc.subjectMedicine
dc.subjectInternal medicine
dc.subjectDiabetes mellitus
dc.subjectType 2 diabetes
dc.subjectHeart failure
dc.subjectMyocardial infarction
dc.subjectPopulation
dc.subjectStroke (engine)
dc.titleA Comparison of Cardiovascular Benefits of Dapagliflozin and Empagliflozin in Type 2 Diabetes: A Systematic Review and Meta-analysis
dc.typearticle

Files

Collections

Artículo Científico Publicado